NU SKIN ENTERPRISES, INC. NUS
NYSE · XNYS · stock · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Chart by TradingView
6/9
Piotroski F — financial health
7.36
Altman Z″ — distress risk · safe
7.4%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.5B | $160.2M | $1.0B | $46.0M | $805.2M |
| 2024 | $1.7B | -$146.6M | $1.2B | $70.2M | $651.5M |
| 2023 | $2.0B | $8.6M | $1.4B | $60.1M | $822.0M |
| 2022 | $2.2B | $104.8M | $1.6B | $49.0M | $897.3M |
| 2021 | $2.7B | $147.3M | $2.0B | $73.0M | $912.8M |
| 2020 | $2.6B | $191.4M | $1.9B | $315.3M | $894.3M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.36 (safe)
- Working capital / assets 0.202
- Retained earnings / assets 1.324
- EBIT / assets 0.047
- Equity / liabilities 1.342
Source: SEC EDGAR filings · CIK 0001021561 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.